Search

Search Constraints

You searched for: Subject 7 -- 3

Search Results

4. Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1 > 50%: Comparison between clinical trials and the real world. Issue 28 (1st October 2022)